Priority Review in Head and Neck Cancer, FDA Approval in GBM, European Approval in MCL, and More

Experts Weigh in on Topic of Frontline Osimertinib Alone or With Chemo in EGFR-Mutant NSCLC

Dr Sands on the Evolving Role of ADCs in SCLC Management

Dr Hirsch on the Treatment of NRG1 Fusion+ NSCLC

MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer